uric acid has been researched along with Inflammatory Bowel Diseases in 11 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Inflammatory Bowel Diseases: Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study was conducted to investigate inosine, a potent immunomodulator, in 2,4,6-trinitrobenzene sulphonic acid (TNBS)-induced chronic model of experimental colitis, and contribution of adenosine A(2A) receptors and the metabolite uric acid as possible underlying mechanisms." | 7.76 | Adenosine A2A receptors and uric acid mediate protective effects of inosine against TNBS-induced colitis in rats. ( Bahremand, A; Daneshmand, A; Dehpour, AR; Fakhfouri, G; Mohammadi, H; Mousavizadeh, K; Rahimian, R; Rasouli, MR, 2010) |
| " This study was conducted to investigate inosine, a potent immunomodulator, in 2,4,6-trinitrobenzene sulphonic acid (TNBS)-induced chronic model of experimental colitis, and contribution of adenosine A(2A) receptors and the metabolite uric acid as possible underlying mechanisms." | 3.76 | Adenosine A2A receptors and uric acid mediate protective effects of inosine against TNBS-induced colitis in rats. ( Bahremand, A; Daneshmand, A; Dehpour, AR; Fakhfouri, G; Mohammadi, H; Mousavizadeh, K; Rahimian, R; Rasouli, MR, 2010) |
| " All of the above RCTs showed that probiotics did not increase the incidence of adverse events." | 2.82 | Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: A systematic review and meta-analysis of 34 randomized controlled trials. ( Chen, H; Deng, Y; He, Q; Li, J; Liu, H; Xiang, W; Yang, K; Zeng, L; Zhu, X, 2022) |
| "Uric acid content was highest when colon surgery had occurred." | 1.32 | Urine stone risk factors in nephrolithiasis patients with and without bowel disease. ( Coe, FL; O'Connor, RC; Parks, JH; Worcester, EM, 2003) |
| " The paradoxical effect observed with probenecid was not seen in the E3040 dose-response curve for the uric acid excretion rate." | 1.30 | Mechanism of the uricosuric action of E3040, a drug used to treat inflammatory bowel disease II: study using DBA/2N mice. ( Furitsu, H; Iga, T; Kotaki, H; Sawada, Y; Yamada, H, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Zeng, L | 1 |
| Deng, Y | 1 |
| He, Q | 1 |
| Yang, K | 1 |
| Li, J | 1 |
| Xiang, W | 1 |
| Liu, H | 1 |
| Zhu, X | 1 |
| Chen, H | 1 |
| Xie, XQ | 1 |
| Geng, Y | 1 |
| Guan, Q | 1 |
| Ren, Y | 1 |
| Guo, L | 1 |
| Lv, Q | 1 |
| Lu, ZM | 1 |
| Shi, JS | 1 |
| Xu, ZH | 1 |
| Rahimian, R | 1 |
| Fakhfouri, G | 1 |
| Daneshmand, A | 1 |
| Mohammadi, H | 1 |
| Bahremand, A | 1 |
| Rasouli, MR | 1 |
| Mousavizadeh, K | 1 |
| Dehpour, AR | 1 |
| Parks, JH | 1 |
| Worcester, EM | 1 |
| O'Connor, RC | 1 |
| Coe, FL | 1 |
| Bairaktari, ET | 1 |
| Kakafika, AI | 1 |
| Pritsivelis, N | 1 |
| Hatzidimou, KG | 1 |
| Tsianos, EV | 1 |
| Seferiadis, KI | 1 |
| Elisaf, MS | 1 |
| Reynolds, TM | 1 |
| Buffinton, GD | 1 |
| Doe, WF | 1 |
| Yamada, H | 2 |
| Kotaki, H | 2 |
| Furitsu, H | 2 |
| Sawada, Y | 2 |
| Iga, T | 2 |
| McLeod, RS | 1 |
| Churchill, DN | 1 |
| Fukushima, T | 1 |
| Yamazaki, Y | 1 |
| Sugita, A | 1 |
| Tsuchiya, S | 1 |
3 reviews available for uric acid and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: A systematic review and meta-analysis of 34 randomized controlled trials.
Topics: Arthritis, Rheumatoid; Bone Diseases, Metabolic; Chronic Disease; Dietary Supplements; Gout; Humans; | 2022 |
ACP Best Practice No 181: Chemical pathology clinical investigation and management of nephrolithiasis.
Topics: Acidosis, Renal Tubular; Calcium; Calcium, Dietary; Citrates; Cystinuria; Diet, Protein-Restricted; | 2005 |
Urolithiasis complicating inflammatory bowel disease.
Topics: Humans; Inflammatory Bowel Diseases; Oxalates; Uric Acid; Urinary Calculi | 1992 |
8 other studies available for uric acid and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Influence of Short-Term Consumption of
Topics: Adult; Alkaline Phosphatase; Bacteria; Biomarkers; Creatinine; Fatty Acids, Volatile; Feces; Female; | 2021 |
Adenosine A2A receptors and uric acid mediate protective effects of inosine against TNBS-induced colitis in rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Biomarkers; Colitis; Dietary Supplements; Drug Synergism | 2010 |
Urine stone risk factors in nephrolithiasis patients with and without bowel disease.
Topics: Calcium Oxalate; Calcium Phosphates; Citric Acid; Female; Humans; Hydrogen-Ion Concentration; Inflam | 2003 |
Hypouricemia in individuals admitted to an inpatient hospital-based facility.
Topics: Blood Glucose; Diabetes Mellitus; Glycosuria; Hematologic Neoplasms; Hospital Departments; Humans; I | 2003 |
Depleted mucosal antioxidant defences in inflammatory bowel disease.
Topics: Antioxidants; Colitis, Ulcerative; Crohn Disease; Free Radical Scavengers; Free Radicals; Glutathion | 1995 |
Mechanism of the uricosuric action of the anti-inflammatory drug E3040 used to treat inflammatory bowel disease I: study using a rat model of hyperuricemia.
Topics: Animals; Benzothiazoles; Disease Models, Animal; Inflammatory Bowel Diseases; Inulin; Kidney Tubules | 1999 |
Mechanism of the uricosuric action of E3040, a drug used to treat inflammatory bowel disease II: study using DBA/2N mice.
Topics: Animals; Benzothiazoles; Gastrointestinal Agents; Inflammatory Bowel Diseases; Male; Mice; Mice, Inb | 1999 |
Prophylaxis of uric acid stone in patients with inflammatory bowel disease following extensive colonic resection.
Topics: Adult; Bicarbonates; Colectomy; Female; Humans; Hydrogen-Ion Concentration; Incidence; Inflammatory | 1991 |